Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Elizabeth Philippe

Family Medicine Cutler Bay, FL Medical Doctor

NPI 1639238488 CMS profile 300776

10300 Sw 216Th St, Cutler Bay, FL 33190

Open in the dashboard

General payments

$3,057

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Elizabeth Philippe of Cutler Bay, FL is reported in the CMS Open Payments database as having received $3,057 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $436 12
2024 General $409 12
2023 General $664 27
2022 General $652 18
2021 General $357 19
2020 General $128 7
2019 General $411 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Elizabeth Philippe
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Elizabeth Philippe were reported at $436. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Elizabeth Philippe Family Medicine median Middle half National median
2019 $411 $150 $41–$543 $163
2020 $128 $120 $32–$415 $114
2021 $357 $137 $35–$551 $132
2022 $652 $137 $37–$512 $149
2023 $664 $149 $42–$545 $160
2024 $409 $156 $44–$560 $164
2025 $436 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $537 24 payments
  2. Boston Scientific Corporation $473 6 payments
  3. Gilead Sciences, Inc. $391 25 payments
  4. ViiV Healthcare Company $308 10 payments
  5. AstraZeneca Pharmaceuticals LP $182 6 payments
  6. Coloplast Corp $167 1 payment
  7. Janssen Pharmaceuticals, Inc $141 8 payments
  8. Inspire Medical Systems, Inc. $132 1 payment
  9. AbbVie, Inc. $91 4 payments
  10. Teva Pharmaceuticals USA, Inc. $60 4 payments
  11. Other $575 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,057 115 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN FLX $384 5 payments
  2. DOVATO $274 9 payments
  3. MINIMED 770G $204 12 payments
  4. INPEN SMART INSULIN DELIVERY SYSTEM $188 2 payments
  5. Titan $167 1 payment
  6. MINIMED 780G $145 10 payments
  7. INSPIRE $132 1 payment
  8. SPRAVATO $120 7 payments
  9. INVEGA SUSTENNA $108 6 payments
  10. AMS $90 1 payment
  11. Other $1,405 68 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

1,823

Median for Family Practice: 1,826

Drug cost

$952,446

Median for Family Practice: $120,094

Branded share of claims

41%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 55 $221,847
Xtandi Enzalutamide Brand 11 $159,641
Odefsey Emtricitab/Rilpiviri/Tenof Ala Brand 39 $135,856
Dovato Dolutegravir Sodium/Lamivudine Brand 19 $59,959
Stribild Elviteg/Cob/Emtri/Tenofo Disop Brand 13 $54,122
Januvia Sitagliptin Phosphate Brand 39 $53,475
Ozempic Semaglutide Brand 35 $42,730
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 12 $42,252
Jardiance Empagliflozin Brand 26 $39,827
Tivicay Dolutegravir Sodium Brand 16 $36,278

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$606

Medicare's payments for the services billed

Medicare patients

23

Average age 68

Services billed

70

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $87
$87 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $23
$23 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record